GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Fatty Liver Disease/Gut–Brain Signalling in Eating and Obesity: Nature Reviews Gastroenterology & Hepatology | August 2026
7

Gut–Brain Signalling in Eating and Obesity: Nature Reviews Gastroenterology & Hepatology | August 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2026

Introduction:

Eating behaviour is governed by complex interactions between the gastrointestinal tract and the brain that generate hunger, satiation, and satiety. This review examines how gut-derived mechanical and nutrient signals are transmitted and integrated within the nervous system to regulate food seeking, meal consumption, food preference, and energy balance, with particular emphasis on the vagus nerve.

Why was this study needed?

. Obesity cannot be fully explained by energy intake and expenditure without considering neural regulation of eating behaviour.

. The mechanisms linking gastrointestinal signals to hunger, reward, satiety, and food-related learning are increasingly understood but remain fragmented.

. Chronic high-fat and high-sugar diets can directly disrupt gut–brain communication.

. Understanding these pathways could reveal therapeutic targets beyond conventional appetite-suppressing treatments.

Results:

Eating is conceptualized across three interconnected phases: food seeking, food consumption, and non-prandial activity, with transitions controlled by interoceptive signals reflecting nutritional and energy status. The vagus nerve serves as a major conduit carrying mechanical and chemical information from the gastrointestinal tract to the brain. Specialized vagal sensory neurons encode distinct signals that influence meal size, nutrient preference, reinforcement, and memory. These signals interact with brainstem, hypothalamic, dopaminergic, and hippocampal circuits to coordinate homeostatic and reward-driven eating.

Chronic exposure to high-fat, high-sugar diets can impair this regulatory system through vagal desensitization and structural remodeling, altered neuronal gene expression, and leptin resistance. Consequently, physiological control of eating becomes disrupted, promoting hyperphagia, biased food preferences, and habitual overeating.

Clinical Impact:

The gut–brain axis represents an important therapeutic frontier in obesity. Although GLP-1 receptor agonists effectively reduce appetite and body weight, they might not fully reverse the underlying neural abnormalities driving maladaptive eating. Targeting specific vagal sensory pathways could potentially restore physiological interoceptive control and complement current pharmacological obesity treatments.

Bottom Line:

Disrupted gut–brain communication—particularly impaired vagal signalling—is a key mechanism driving maladaptive eating and obesity, making vagal circuits a promising target for next-generation obesity therapies.

Related Q&A

08

AI-Powered Blood Test Detects Liver Cancer Across Diverse Populations: Cell | July 2026

Researchers at Johns Hopkins have validated an AI-powered DELFI liquid biopsy that accurately detected hepatocellular carcinoma (HCC) in geographically and biologically distinct high-risk populations. Key findings: ✅ Successfully...

09

LITMUS Imaging Study for MASH and Fibrosis: Nature Medicine | July 2026

Introduction: Reliable noninvasive biomarkers are essential to replace liver biopsy for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and staging fibrosis. The prospective multicenter LITMUS Imaging Study evaluated the diagnostic...

10

Fibrosis Remains the Strongest Predictor of Outcomes in Global-MASLD Study: Hepatology | July 2026

Introduction: Fibrosis is the principal determinant of long-term outcomes in metabolic dysfunction–associated steatotic liver disease (MASLD). This large international Global-MASLD study evaluated clinical predictors of advanced fibrosis and...

11

Beyond BMI: Contemporary Guidelines for Obesity Care: Nature Reviews Endocrinology | July 2026

Introduction: Obesity is increasingly recognized as a chronic, adiposity-based disease rather than a condition defined solely by body mass index (BMI). Recent guidelines from major international organizations have...

12

Global Performance of Noninvasive Fibrosis Tests in MASLD: Hepatology | July 2026

Introduction: Noninvasive tests (NITs) have become central to the diagnosis and staging of metabolic dysfunction–associated steatotic liver disease (MASLD), reducing reliance on liver biopsy. However, most validation studies...

13

FMO Score for Identifying At-Risk MASH in Obesity: Hepatology | July 2026

Introduction: Identifying patients with at-risk metabolic dysfunction–associated steatohepatitis (MASH) is essential because they carry a substantially higher risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although liver biopsy...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer